CRISPR Gene Therapy Shows Durable Cholesterol Reduction in Phase 2 Trial
Experimental CRISPR Therapy Achieves Year-Long Cholesterol Reduction
A single injection of an experimental CRISPR gene-editing therapy has produced substantial and lasting reductions in "bad" cholesterol (LDL) and triglycerides in patients with challenging-to-treat lipid disorders. The findings come from a Phase 2 clinical trial, where researchers observed that a single dose led to approximately 50% reductions in both LDL cholesterol and triglycerides that remained stable over a full year of follow-up.
In the highest-dose group, patients experienced a 52.5% reduction in LDL cholesterol alongside a 47.8% drop in triglycerides. The durability of these effects is particularly notable, as the treatment appeared to permanently modify the target genes responsible for cholesterol regulation rather than requiring ongoing administration.
The therapy works by using CRISPR-Cas9 gene editing to disable specific genes in the liver that regulate lipid metabolism. Unlike daily medications such as statins, this approach aims to provide a long-term or potentially permanent solution with just one treatment.
Researchers noted that the adverse event profile was generally mild to moderate, with no patients discontinuing due to side effects. The results support further development of this approach for patients who cannot tolerate or adequately respond to conventional lipid-lowering therapies.
Phase 3 trials are anticipated to further evaluate the therapy's efficacy and safety in broader patient populations.